Table 1.

Number of patients with EGFR-mutant NSCLC patients with brain metastases who received EGFR-TKI after BM diagnosis.

Group	n	Follow-Up Time
Total EGFR-mutant NSCLC patients treated with EGFR-TKI after BM diagnosis	107	17.1 months
Treated with first-generation EGFR-TKI (erlotinib/gefitinib), n	64	18.03 months
Treated with first-generation EGFR-TKI (Osimertinib), n	50	17.95 months